List of Antibodies Companies in Germany - 48

Cardiogenic Shock: the primary circulatory shock in ICUs with a mortality rate over 70%. Triggered by acute myocardial injuries like heart attacks, it leads to severe left-ventricular dysfunction. Despite advancements in care and treatment for up to 200,000 affected U.S. patients annually, the first 30 days after diagnosis see persistently high mortality rates of 50-70%. Understand its pathophysiology, including the critical role of Dipeptidyl Peptidase 3, and the latest interventions.

Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Enibarcimab is a first-in-class monoclonal antibody. Enibarcimab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Enibarcimab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock.

Personalised therapies for the heart and vasculature Innovative, independent, close to the patient. We are a biotech company that independently develops innovative drugs and diagnostics for personalised treatment of cardiovascular diseases. We have a unique product pipeline that we are consistently moving into clinical trials. Our lead compound has been successfully tested in two Phase II studies. We work closely together with excellent academic and clinical teams in basic and clinical research. We use state-of-the-art analytical methods, and we develop our products according to the highest quality standards (GLP, GMP and GCP). Revacept is a therapeutic agent for the prevention and treatment of acute arterial thrombosis, which can lead to heart attack, acute limb ischemia and stroke. A Phase II clinical trial in 160 patients with stroke or transient ischaemic attack (TIA) has been completed. It showed beneficial effects in patients treated with 120 milligrams (mg) of Revacept. Another Phase II clinical trial investigated Revacept in 332 patients with stable coronary artery disease (ISAR-PLASTER) has been completed. This study conducted by the German Centre for Cardiovascular Research (DZHK) confirmed the very good tolerability of Revacept. Overall, Revacept did not lead to increased bleeding despite of its additional platelet aggregation inhibition on top of conventional standard therapy. It decreased ischemic strokes in NMR and improved the net clinical benefit of MACE and bleeding. Recently, the FDA has approved the preclinical and clinical development and the further phase 3 protocol until market approval. Antibody therapeutic In collaboration with Morphosys an anti-GPVI Fab antibody has been discovered. The candidate is currently in preclinical evaluation for the treatment of acute coronary syndrome and stroke. Imprint: https://www.advancecor.de/imprint/ privacy policy: https://www.advancecor.de/privacy-policy/

We are a research-oriented provider of innovative, efficient products and services for early detection, diagnosis and prognosis of autoimmune and infectious diseases, allergies and food intolerances. We strive to improve the diagnosis and management of different diseases as a provider of innovative in-vitro diagnostic products that really work. Built on a tradition of innovation and an interdisciplinary knowledge network, AESKU.DIAGNOSTICS offers unique diagnostic options: faster, more efficient and reliable test systems designed to improve clinical outcomes for the benefit of patients and physicians. Follow us on our other Social Media Profiles. https://www.linkedin.com/company/dst-diagnostische-systeme-&-technologien-gmbh/about/ instagram: https://www.instagram.com/aesku.group/ Contact us: Website: www.aesku.com⁠ E-Mail: socialmedia@aesku.com⁠

At Affimed, we are committed to improving outcomes for patients with cancer. Our scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unique approach to fighting cancer. With our unparalleled expertise in innate immunity and innate cell engager-based medicines, we aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

ANTITOXIN GmbH is a biotechnology company that specializes in producing Blood Typing Antisera and Rare Sera for various blood groups.

Apogenix develops innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby reducing lymphopenia and inflammatory cell death in patients with viral infections and restoring the anti-tumor immune response in cancer patients.

Aptarion is dedicated to leveraging the strengths of biostable L-aptamers (highly specific "chemical antibodies") across the biomedical spectrum. Besides the discovery of new L-aptamers for the functionalization of sensors with its powerful platform technology, Aptarion pursues the development of its proprietary existing L-aptamers as therapeutics in areas of high medical need.

Berlin Cures was first to follow up on the scientific finding that there are a large number of diseases associated with pathological functional autoantibodies directed against G protein-couples receptors. Heart failure and Long Covid belong to this group of diseases. Our aptamer BC 007 can neutralize these autoantibodies and this is the reason why Berlin Cures has been working for decades to develop a product based on scientific findings that may help many suffering patients.

BioCopy is a Swiss-German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in today's pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and develop-ment time of next-generation biotherapeutics from approx. 3 years to 12 months. It will save valuable time in the fight against cancer and significantly reduce the cost of cancer therapeutics. In the long term, BioCopy will expand its efforts beyond cancer and develop biotherapeutics for immunological and neurological diseases. The company is managed by Dr Matthias Wiedenfels, a proven expert and industry insider in the pharmaceutical and biotechnology industry, not least through his time as CEO of STADA Arzneimittel AG.

BioGenes is a full-service provider of customized immunoassay and antibody development, with a strong commitment to quality and service. Founded in 1992 and headquartered in Berlin, Germany, BioGenes is a recognized partner serving more than 600 customers in 40 countries. The company maintains long-term relationships with global pharmaceutical, biotech companies, CMOs and in vitro diagnostic firms. BioGenes provides highly customized solutions for the quality control of biological products, from drug discovery and drug development to the manufacturing of biologicals, as well as for diagnostic purposes.

 The company specializes in sophisticated custom monoclonal, polyclonal and anti-idiotypic antibody development and has a proven track record in the development, optimization, pre-validation and production of highly sensitive and robust ELISAs and host cell protein (HCP) assays. Furthermore, BioGenes offers the enhanced generic 360-HCP ELISA kits and supports customers with a comprehensive range of analytical services.

BioNTech is a global next generation immunotherapy company aspiring to translate science into survival. Around 6.100 pioneers currently work with us, employing a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules.   Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. To learn more about us, please visit www.BioNTech.com. Our privacy statement can be found here:  https://www.biontech.com/int/en/home/data-privacy-statement.html Our imprint can be found: https://www.biontech.com/int/en/home/imprint.html

Biotest is a specialist supplier of plasma proteins and biotherapeutic drugs used to treat diseases of the immune system or the haematopoietic system. The value chain of the medium-sized company, which was founded in 1946 as a family business, ranges from pre-clinical and clinical development to worldwide marketing. Biotest specialises primarily in the fields of clinical immunology, haematology as well as intensive care and emergency medicine. As the world market leader in hyperimmunoglobulins and the only manufacturer of IgM-enriched immunoglobulins, Biotest sees itself as an expert for innovative products for the prevention and therapy of life-threatening and rare infections. In addition, Biotest supports doctors and patients with coagulation factors that are also produced on the basis of human blood plasma. Among other things, the company has state-of-the-art plasmatic factor VIII and factor IX concentrates for the treatment of the congenital coagulation disorders haemophilia A and haemophilia B. Since 2019, the product portfolio also includes a first recombinant FVIII preparation from a human cell line. Biotest currently employs more than 2,000 people worldwide, the majority of whom are based at the company's headquarters in Dreieich near Frankfurt. The internationally active specialist supplier has subsidiaries in eight countries and sells its products in more than 80 countries. The plasma used is mainly obtained in the company's 22 plasma collection centres in Europe and meets the strictest official safety and quality requirements. Biotest manufactures all products exclusively in Germany.

CatalYm is a Germany-based biotechnology company that researches and develops gene therapies for the treatment of cancer.

Celonic is a "Pure Play" Biologics Contract Development Manufacturing Organization (CDMO). Celonic's mission is to help its customers, primarily small to large Biotech Companies, bring life-saving and improving drugs effectively to the market using innovative, "next generation" bioprocessing technologies such as, process intensification and full-perfusion. Celonic has a state-of-the-art Development and Innovation Center in Basel, Switzerland (headquarters), and clinical and commercial GMP manufacturing facilities in Heidelberg, Germany. At present, more than 500 highly qualified employees work at Celonic. Due to the expansion of the company, Celonic is looking for committed and qualified employees. Our job is to make a difference!

CORAT develops phage-display derived fully human antibodies into passive vaccines to treat and to protect against COVID-19

We at CYTENA strive to empower our customers to serve patients faster and better. To accelerate workflows and bring new insights into biotherapeutic drug development, we provide precise control of individual cells through automation and microtechnology. Our instruments offer automated isolation of single cells with assurance of clonality and selection based on cell morphology. We can isolate many common cell types including bacteria. Our high viability rates make our instruments compatible with cell line development, single cell analysis, and other downstream applications. Most of the top ten largest pharmaceutical companies have successfully integrated cytena instruments into their workflows to quickly produce monoclonal cell lines for antibody development with minimal risk of cross-contamination. cytena instruments are also used for academic research for various topics including cancer, autoimmune disease and genomic research. Our instruments provide many benefits including: Assurance of clonality Every single cell isolated is imaged to provide assurance of clonality. The image sequence is assigned to the well of the deposited cell and stored for documentation. Viability Our instruments gentle handling routinely achieves high cell viability without the need for cell labelling. Purity A disposable cartridge is the only component in contact with the cells ensuring no cross-contamination between samples and no cleaning routines. Easy to use and flexible Our instruments and software are intuitive, user friendly, and can be readily implemented into existing structures and workflows. Interested in joining our team? cytena is a young, dynamic and highly motivated team. We are looking for new team members who also have interest in developing new and innovative products. Feel free to contact us if you have any inquiries on current open positions.

DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients.

EUROIMMUN'un uzmanlık alanı immünoloji, hücre biyolojisi, histoloji, biyokimya ve moleküler biyolojidir. Otoimmün ve enfeksiyöz hastalıkların, alerjilerin ve gen analizlerinin laboratuvar tanısı için test sistemleri üretir. Hasta numunelerinde antikorların tespiti için test sistemleri ön planda olmakla birlikte, antijenler ve genetik markerlar da mevcuttur. Bunlar, indirekt immünofloresan, mikrotitreli ELISA'lar ve farklı blot teknikleri (Westernblot, EUROASSAY, EUROLINE, EUROLINE-WB) ve moleküler biyolojik (mikroarray) teknikler gibi immünohisto-kimyasal ve biyokimyasal yöntemlere dayanmaktadır. EUROIMMUN üretimini, dünya çapında patentleri taşıyan modern, son teknoloji prosedürleri ve mikroanaliz tekniklerine dayandırır. Şirket, tıbbi laboratuar teşhis ürünlerinin lider üreticilerinden biridir. Ürünlerimiz Avrupa, Amerika, Asya, Avustralya ve Afrika'da yaklaşık 130 ülkede kullanılmaktadır.   Aralık 2017 itibariyle, Amerikan PerkinElmer firması, EUROIMMUN hisselerinin çoğunluğunu elinde tutmaktadır. PerkinElmer medikal ve biyoteknoloji alanında uluslararası bir liderdir. Yenilikçi tespit ve görüntüleme teknikleri ve IT sistemleri ile, teşhis, tıbbi araştırma, çevre ve gıda analizlerinde kapsamlı uzmanlık sağlar.

What we do: we supply therapeutic molecules of clinical-grade quality for R&D and early drug development. Our solution: we repackage pharmaceuticals. So, we offer aliquots of clinical-grade mAbs, bs-mAbs, fusion proteins, ADCs, and other biologics as laboratory consumables. As an additional service, we provide analytical data to accompany each aliquot. Your advantage: you can order therapeutic molecules in clinical-grade quality as research consumables. Fast . Easy. Cost efficient.

Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies. We combine expertise in glycobiology and know-how in antibody development to advance first-in-class antibody-based therapeutics for (immuno)-oncology. Our antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GlycoTargets). Based on their superior tumor-specificity, our antibodies are suitable for development in an array of different modes of action including naked antibodies, bispecifics, antibody-drug-conjugates, cellular therapies or fusion-proteins. Glycotope has to date discovered in excess of 200 GlycoTargets with several antibodies against selected targets under development.

Heidelberg Pharma AG based in Ladenburg, Germany, is a biopharmaceutical company listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard. Heidelberg Pharma is focused on oncology and is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary platform is being applied to develop the Company’s own therapeutic ATACs and third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. Former clinical assets MESUPRON® and REDECTANE® have been partnered. Our mission is to research and develop therapies for cancer patients enabling them to receive a targeted and tailor-made course of treatment that is both highly effective and as well-tolerated as possible.

Immundiagnostik – Closing the Gaps in Laboratory Diagnostics Immundiagnostik AG, founded in 1986, is a globally operating diagnostics company represented in over 30 countries. We focus on the development and production of innovative immunoassays (ELISA, EIA) and other analytical detection methods (e.g. HPLC and PCR) for medical routine and research. Furthermore, we offer a broad portfolio of antibodies and antigens. Our business relations include contract analyses for diagnostic laboratories and academic research institutions, esp. in context with clinical trials. Multiple cooperations with the pharmaceutical industry and a tight network with scientific organisations are the basis of a successful product development. Securing progress: Our comprehensive range of products is continuously refuelled by a rich pipeline of proprietary developments. With a headcount of more than 50 employees, Immundiagnostik's headquarter is located in Bensheim, south-western Germany.

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com

iOmx is a young, dynamic start-up in the field of immuno-oncology located in Martinsried/Munich, Germany. Backed by a powerful technology platform and internationally renowned investors, iOmx is driving forward a cutting-edge portfolio of early-stage novel immune-checkpoint drugs through pre-clinical and clinical development.

Lindis Biotech, Munich, is a clinical stage bio-pharmaceutical company that is committed to the development of Triomab® antibodies.

For over 30 years, Miltenyi Biotec has been a major provider of products and services that drive biomedical research and boost cell and gene therapy. More than 4,700 employees in 23 countries combine excellence in research with innovative products to create cutting-edge solutions that make cancer and other disease history. Our expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. At Miltenyi Biotec, scientists, engineers, software developers and many other professionals work together to improve human health by providing smarter cellular technology solutions to researchers and clinicians worldwide.

multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform on the basis of the founding scientists'​ (Professor Gabriele Multhoff, Dr Claus Botzler) discovery that cell surface-bound Hsp70 is uniquely expressed on a large proportion of cancers (~50-75%), but not on healthy cells. This makes this form of Hsp70 an excellent and broadly-applicable molecule on which to base the development of innovative therapeutics and diagnostics (theranostics). Based on its discovery of membrane Hsp70, multimmune has succeeded in developing a powerful pipeline of cancer therapeutics. ENKASTIM allows, for the first time, a unique and specific activation of human natural killer (NK) cells which are programmed to recognise and kill cancers expressing membrane Hsp70 via the release of a cytotoxic molecule called granzyme B. These cells destroy tumors and metastases that are invisible to the cell killing (cytolytic) consequences of more conventional T cell-based immunotherapies. Hsp70-expressing tumors can also be targeted using therapeutics based on a unique monoclonal antibody which can detect the membrane form of Hsp70. multimmune's lead diagnostic candidate is the patented and CE-marked Hsp70-exo enzyme immunoassy (ELISA) which detects lipid-associated Hsp70 in the peripheral circulation, levels of which can be used to detect the presence of tumors expressing membrane Hsp70, as well as monitoring therapeutic response and disease recurrence.

Navigo Proteins discovers and develops novel scaffold proteins-based affinity ligands for commercial biologics GMP purification or as biopharmaceutical drugs/binders. They are all small, stable, highly engineerable, selective, and economically, homogeneously producible. In PRECISION CAPTURING a protein A-like scaffold serves for an antibody-like capture step even of non-Fc bearing molecules. In PRECISION TARGETING human ubiquitin is the basis for highly selective Affilin® ligands as part of a broad range of biopharmaceutical drugs. Navigo Proteins’ unique protein engineering expertise is the basis a world-wide unique, versatile scaffold proteins platform. Our robust, rapid and reliable high-throughput-based, robotics assisted platform designs, produces, analyzes and selects suitable affinity ligand proteins, optimized for their tasks in industrial downstream processing or as biopharmaceutical drugs. PRECISION CAPTURING creates custom ligands against any biologic, Fc-independent, and enables antibody-like affinity downstream processes, with competitive binding capacities, caustic stabilities, usage-cycles, flow rates and commercially available off-the-shelf leaching assays. It is applicable for purifying any recombinant protein, mAb, virus, VLP, cell, etc. Navigo Proteins has established partnerships worldwide to convert its custom affinity ligands into ready-to-use, GMP-compliant affinity resins for commercial downstream processing. Our PRECISION TARGETING platform creates tailored ligands which bind any desired biologic in biopharmaceutical or in diagnostic use, e.g. radiopharmaceuticals, Protein-drug-conjugates, CAR-T ligands or theranostics, in which the same Affilin® binder is employed in diagnosis, treatment and treatment-monitoring. Navigo Proteins is about 50 heads strong, steadily growing and based in Halle, S/W of Berlin. We offer our expertise to interested pharma, biotech and life sciences companies. https://www.navigo-proteins.com/imprint

PEPperPRINT is an innovative biotech company from Heidelberg, Germany, and the leading provider of high density peptide and protein microarrays for antibody characterization or the fingerprint analysis of antibody responses from biological samples. The product and service portfolio was recently complemented by T cell epitope mapping and monitoring, making PEPperPRINT a one-stop solution provider for the fingerprint analysis of immune responses e.g. for epitope mapping, antibody biomarker discovery or the analysis of adverse immune effects. PEPperPRINT’s peptide microarrays and screening services have been used by researchers around the world with over 200 peer-reviewed publications.

ProBioGen is a renowned contract development and manufacturing organization (CDMO) and technology provider. We perform cell line engineering, process development, and GMP manufacturing of biopharmaceuticals for clients in biotech and pharma. We offer proprietary innovative technologies for optimized biopharmaceutical manufacturing and analysis. ProBioGen also provides process development services and manufacturing technologies for viral vaccines. Our additional new building houses 1000 L single-use bioreactor capacity to keep up with the ever-increasing demand from our clients. A second 1000 L single-use bioreactor is coming soon. With 30 years of experience in animal cell culture, combined with innovative scientific excellence and a strong intellectual property base, we cover the entire drug development value chain end-to-end. Watch & learn more: https://youtu.be/vtEgrEVfj70

Our commitment to scientists is to support them in making new scientific discoveries and groundbreaking research within the life sciences and gene therapy. It is our underlying mission, to help progress new therapies safely, quickly and affordably, so together we can provide solutions to people suffering from poor health and affected by disease every day. PROGEN is made up of a team of experts within AAV and the life sciences and is partnered with gene therapy experts worldwide. We are more than just a manufacturer of antibodies, proteins and ELISAs kits. We strive to understand what scientists need, so we can create solutions and ultimately deliver high quality antibody and exclusive AAV products, which solve your research challenges within academia, biotech and pharma, and ensure PROGEN can continue to be a trusted and reliable partner. Visit our website www.progen.com Imprint: https://bit.ly/3uEZf2h Privacy Statement: https://bit.ly/3dMSgxm

Transforming proteins into pioneering drugs ProJect Pharmaceutics, based in Martinsried/Munich, Germany, transforms proteins, peptides and delicate small molecules into pioneering drugs. ProJect Pharmaceutics adds value to client´s bio-pharmaceutical products by applying an innovative concept of development called Advaceutics. Based on the Advaceutics concept, ProJect Pharmaceutics designs optimized formulations and delivery systems for biologics that are stable, convenient and safe. Tailored to these optimized systems the company develops cost-effective manufacturing processes and transfers those from its own pilot labs to large-scale manufacturing. ProJect Pharmaceutics makes sure that investigational products, biosimilars as well as "bio-betters" are developed effectively and will run smoothly in clinical and commercial scale GMP manufacturing. We offer: • predictive formulation analytics • formulation development including in-depth protein analytics • lyophilization process development and optimization • lyophilization in dual chamber prefilled syringe • development of liposomal formulations, producible by simple stirring • manufacturing of preclinical study material • technology-transfer including scale-up to GMP-manufacturer We deliver: • optimized formulations for biopharmaceuticals • tailored manufacturing processes and transfer to GMP manufacturing • development reports ready for submission to the authorities for registration

QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31 2021 QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.

Protein profiling plays a crucial role in the advancement of biomedical research, enabling us to improve patients' quality of life by utilizing molecular signatures for accurate diagnosis and treatment. At Sciomics, our passion for advanced protein profiling is driving the future of Precision Medicine. We are continually expanding our biomarker signature pipeline to address a wide range of clinical indications and to advance Precision Diagnostics. Our cutting-edge services enable scientists worldwide to unravel the complexities of disease, uncover modes of action and identify promising protein biomarker candidates. Our service portfolio is anchored in our state-of-the-art scioDiscover microarray platform for protein and post-translational modification profiling. We are proud to support a wide range of research, from basic scientific discovery to breakthrough pharmaceutical initiatives (R&D). scioDiscover is a high-content, high-throughput system that provides a fast and cost-effective solution to your research needs. Its results are seamlessly translated into validation and clinical assays, enabling breakthrough biomarker discovery and preclinical drug development. Our team is dedicated to supporting you throughout your project: Project Planning: From planning to execution, we will help you navigate the most efficient route to achieve your research objectives. Technical Expertise: Our team provides unmatched proficiency in your proteomic analysis endeavors. Customized Solutions: We provide customized solutions to meet your specific research needs. Comprehensive Study Report: Our services include a comprehensive data analysis and a customized report. Our Platform Is Used For: • Protein Biomarker Identification and Verification • Novel Drug Target Discovery • Mode-of-Action Analysis • Pathway Activity Analysis • Disease Model Characterization, among other key applications Join us on our mission to revolutionize medicine! #PrecisionMedicine #Proteomics

SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening diseases. Founded in late 2016, we develop first-in-class antibodies against iRhom2, a key modulator of several crucial pro-inflammatory signalling pathways, including TNF-alpha signalling. Following the preclinical and early clinical development of these monoclonal antibodies, we are aiming to provide superior treatment options to currently existing inhibitors of TNF-alpha signaling. SciRhom is poised to transform the lives of patients with autoimmune diseases.

SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in humans and all pharmacologically relevant model species. Antibodies comprising epitopes of 4 amino acids are the key reagents of SIGNATOPE´s immunoassays.

SYNIMMUNE GmbH is a biotechnology company focusing on the development of novel mono- and bispecific antibodies for improved immunotherapy of cancer.

Tacalyx develops the next generation of anti-Cancer therapeutics in indications with high medical need

Treamid Therapeutics GmbH was founded in 2016 with the aim to develop new and innovative treatments for respiratory and inflammatory diseases. All our small molecules are under global patent protection. Our aim is to develop new drugs in the area of high unmet need for respiratory and inflammatory disease, supporting patients with new innovative and easily accessible medications. We are collaborating with well-renowned institutions and CROs in different fields of our research and development. We also have our own in vitro lab driving our research and developing new methods to further investigate our molecules in different disease areas.

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

VERAXA Biotech specializes in ADC development combining cutting-edge solutions for targeted antibody discovery and bioconjugation. Through biochemical and technological innovation, we strive to transform the way antibodies and antibody-drug conjugates (ADCs) are created to develop more effective and safe therapies for patients. With our transformative technologies, we can streamline and derisk early bioconjugate development. We have established a rich pipeline of proprietary ADCs and are collaborating with a number of partners to provide access to our unique research & development capabilities going from target to antibody to ADC.

INSPIRED BY DEDICATION - that was our credo right from the start and we want to live up to this claim in the future as well! For more than four decades now, Virion\Serion has proven to be a reliable, competent and trusted partner for our customers worldwide. All processes, services and products are managed in accordance with the EU directive 98/79/EG, under a certified quality management system according to DIN EN ISO 13485, to ensure and maintain the highest quality of our products and services. All products are manufactured in Wuerzburg and distributed worldwide.

Vivoryon is focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The mechanisms of action underlying our approach enables us to target a variety of disease areas with high medical need. With historic roots in diabetes research and development as well as neurodegenerative disorders, Vivoryon’s focus is now on applying our approach to developing medicines in inflammatory and fibrotic disorders.

YUMAB Company profile The German biotech company YUMAB was founded in 2012 as spin-off the University of Braunschweig. In little more than five years, YUMAB (a phonetic play on “HUMAB”, which stands for “human monoclonal antibody and in which the “Y” symbolizes the well-known antibody structure) has become a global player in human monoclonal antibody (mAb) development, and drives the general trend in the immunotherapy space toward the use of fully human mAbs for therapeutic applications. The YUMAB® antibody platform provides rapid, reliable and robust development of “state-of-the-art” and “next-generation” fully human antibodies. The technologies base on more than 28 years of continuous research and development of our founders, who are well recognized scientific experts in the field of recombinant antibody technologies and who have an outstanding track-record in academic and industrial research. YUMAB provides optimized antibody development solutions for: i) discovery & development of novel, fully human antibodies, ii) antibody engineering & humanization, and iii) personalized & custom libraries Key features of the YUMAB® platform are: i) world’s best, naturally derived, universal, human antibody libraries (>10e11) ii) powerful in vitro selection technologies including on-cells-selection for difficult targets iii) large scale screening platforms iv) comprehensive portfolio of antibody engineering & humanization technologies v) compatibility to all therapeutic antibody formats YUMAB provides fee for service solutions with attractive pricing and flexible license models & options as well as collaborative projects. YUMAB’s research & development unit performs internal pipeline and partnered projects ranging from the development of novel antibody therapeutics to the discovery to novel targets technologies. Our mission is to make the best human antibody technologies available for the early development to accelerate translation of research from bench to bedsite.